Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2017 | Pages:
259 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Traumatic Brain Injury - Pipeline Review, H1 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2017, provides an overview of the Traumatic Brain Injury (Central Nervous System) pipeline landscape. Traumatic brain injury happens when an external mechanical force causes brain damage. Traumatic brain injury usually results from a violent blow or jolt to the head or body. Symptoms include headache, dizziness, nausea or vomiting, mood changes, fatigue or drowsiness, difficulty sleeping and memory or concentration problems. Risk factor includes age. Certain types of traumatic brain injury increase the risk of developing Alzheimer's disease and coordination problems. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Traumatic Brain Injury - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Traumatic Brain Injury (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Traumatic Brain Injury (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Traumatic Brain Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 7, 3, 1, 56 and 10 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 11 and 1 molecules, respectively. Traumatic Brain Injury (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Traumatic Brain Injury (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Traumatic Brain Injury (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Traumatic Brain Injury (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Traumatic Brain Injury (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Traumatic Brain Injury (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Traumatic Brain Injury (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Traumatic Brain Injury - Overview 9 Traumatic Brain Injury - Therapeutics Development 10 Pipeline Overview 10 Pipeline by Companies 11 Pipeline by Universities/Institutes 16 Products under Development by Companies 17 Products under Development by Universities/Institutes 21 Traumatic Brain Injury - Therapeutics Assessment 22 Assessment by Target 22 Assessment by Mechanism of Action 26 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Traumatic Brain Injury - Companies Involved in Therapeutics Development 34 ALSP Inc 34 Amarantus Bioscience Holdings Inc 34 Apollo Endosurgery Inc 35 Athersys Inc 35 Beech Tree Labs Inc 36 Cognosci Inc 36 Eustralis Pharmaceuticals Ltd 37 Intellect Neurosciences Inc 37 International Stem Cell Corp 38 Ischemix Inc 38 Karyopharm Therapeutics Inc 39 Kyorin Pharmaceutical Co Ltd 39 Levolta Pharmaceuticals Inc 40 Lixte Biotechnology Holdings Inc 40 MandalMed Inc 41 Mapreg SAS 41 Neuralstem Inc 42 Neuren Pharmaceuticals Ltd 42 Neurofx Inc 43 NeuroNascent Inc 43 NeuroVive Pharmaceutical AB 44 New World Laboratories Inc 44 NuvOx Pharma LLC 45 Omeros Corp 45 Oxeia Biopharmaceuticals Inc 46 PharmatrophiX Inc 46 Phylogica Ltd 47 Prevacus Inc 47 QR Pharma Inc 48 RegeneRx Biopharmaceuticals Inc 48 Remedy Pharmaceuticals Inc 49 Sage Therapeutics Inc 49 SanBio Inc 50 STATegics Inc 50 Stemedica Cell Technologies Inc 51 SynZyme Technologies LLC 51 Tetra Discovery Partners LLC 52 Thera Neuropharma Inc 52 vasopharm GmbH 53 VG Life Sciences Inc 53 Traumatic Brain Injury - Drug Profiles 54 (levocetirizine dihydrochloride + montelukast sodium) - Drug Profile 54 2-DG - Drug Profile 55 ALP-496 - Drug Profile 57 AMRS-001 - Drug Profile 59 AST-002 - Drug Profile 68 AST-004 - Drug Profile 69 AVL-8168 - Drug Profile 70 BQ-A - Drug Profile 71 brexanolone - Drug Profile 72 BTL-slo - Drug Profile 81 Cell Therapy to Activate hNT-3 for Spinal Cord and Traumatic Brain Injury - Drug Profile 83 CEVA-101 - Drug Profile 84 CEVA-102 - Drug Profile 86 CHEC-9 - Drug Profile 87 CMX-2043 - Drug Profile 88 CNB-001 - Drug Profile 91 COG-1410 - Drug Profile 93 cyclosporine - Drug Profile 95 dexamethasone acetate + melatonin - Drug Profile 101 EPO-Variant - Drug Profile 102 EUC-001 - Drug Profile 103 felbamate - Drug Profile 104 glyburide - Drug Profile 105 HBI-002 - Drug Profile 109 HBI-137 - Drug Profile 110 HBN-1 - Drug Profile 111 HBN-2 - Drug Profile 112 HPI-201 - Drug Profile 113 HPI-363 - Drug Profile 115 ibudilast - Drug Profile 116 ICCN-100 - Drug Profile 126 ISC-hpNSC - Drug Profile 127 JM-4 - Drug Profile 132 KPT-350 - Drug Profile 133 LB-201 - Drug Profile 135 LB-205 - Drug Profile 136 LM-22A4 - Drug Profile 137 LM11A-31BHS - Drug Profile 139 Lpathomab - Drug Profile 141 MAP-4343 - Drug Profile 144 Monoclonal Antibody for Central Nervous System - Drug Profile 145 Monoclonal Antibody to Inhibit HMGB1 for Influenza A Infections and Nervous System Disorders - Drug Profile 146 Monoclonal Antibody to Inhibit Tau for Central Nervous System Disorders - Drug Profile 147 MW-151 - Drug Profile 148 N-acetyl cysteine amide - Drug Profile 149 ND-478 - Drug Profile 150 Neu-2000 - Drug Profile 151 neuregulin-1 - Drug Profile 153 NFx-101 - Drug Profile 154 NNI-370 - Drug Profile 155 NNZ-2591 - Drug Profile 156 NSI-189 - Drug Profile 158 NSI-566 - Drug Profile 163 NVX-108 - Drug Profile 171 NVX-428 - Drug Profile 172 NWL-53 - Drug Profile 173 NYX-2925 - Drug Profile 174 OXE-103 - Drug Profile 176 PEG-HCC - Drug Profile 177 PF-05285401 - Drug Profile 178 Posiphen - Drug Profile 189 PRV-002 - Drug Profile 192 PYC-35 - Drug Profile 193 PYC-36 - Drug Profile 194 PYC-38 - Drug Profile 195 PYC-98 - Drug Profile 196 R-554 - Drug Profile 197 RGN-352 - Drug Profile 198 ronopterin - Drug Profile 202 SanFlow - Drug Profile 204 SB-623 - Drug Profile 205 Small Molecule to Activate Epsilon PKC for Traumatic Brain Injury - Drug Profile 209 Small Molecule to Antagonize GPR17 for Central Nervous System Disorders - Drug Profile 210 Small Molecules for Traumatic Brain Injury - Drug Profile 211 Small Molecules to Antagonize TLR-4 for CNS Disorders - Drug Profile 212 Small Molecules to Inhibit PBR for Traumatic Brain Injury and Neurodegenerative Diseases - Drug Profile 213 Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology - Drug Profile 214 Stem Cell Therapy for Central Nervous System Disorders - Drug Profile 220 STSE-15 - Drug Profile 221 SYN-2 - Drug Profile 223 SYN-NCE - Drug Profile 224 T-094 - Drug Profile 225 TauC-3 - Drug Profile 226 UH-0113 - Drug Profile 228 UH-0213 - Drug Profile 229 VG-1177 - Drug Profile 230 VitalHeme - Drug Profile 232 VOLT-02 - Drug Profile 233 XN-001 - Drug Profile 234 ZL-006 - Drug Profile 235 Traumatic Brain Injury - Dormant Projects 236 Traumatic Brain Injury - Discontinued Products 239 Traumatic Brain Injury - Product Development Milestones 240 Featured News & Press Releases 240 Appendix 252 Methodology 252 Coverage 252 Secondary Research 252 Primary Research 252 Expert Panel Validation 252 Contact Us 252 Disclaimer 253
List of Tables
Number of Products under Development for Traumatic Brain Injury, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Companies, H1 2017 (Contd..2), H1 2017 Products under Development by Companies, H1 2017 (Contd..3), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Traumatic Brain Injury - Pipeline by ALSP Inc, H1 2017 Traumatic Brain Injury - Pipeline by Amarantus Bioscience Holdings Inc, H1 2017 Traumatic Brain Injury - Pipeline by Apollo Endosurgery Inc, H1 2017 Traumatic Brain Injury - Pipeline by Athersys Inc, H1 2017 Traumatic Brain Injury - Pipeline by Beech Tree Labs Inc, H1 2017 Traumatic Brain Injury - Pipeline by Cognosci Inc, H1 2017 Traumatic Brain Injury - Pipeline by Eustralis Pharmaceuticals Ltd, H1 2017 Traumatic Brain Injury - Pipeline by Intellect Neurosciences Inc, H1 2017 Traumatic Brain Injury - Pipeline by International Stem Cell Corp, H1 2017 Traumatic Brain Injury - Pipeline by Ischemix Inc, H1 2017 Traumatic Brain Injury - Pipeline by Karyopharm Therapeutics Inc, H1 2017 Traumatic Brain Injury - Pipeline by Kyorin Pharmaceutical Co Ltd, H1 2017 Traumatic Brain Injury - Pipeline by Levolta Pharmaceuticals Inc, H1 2017 Traumatic Brain Injury - Pipeline by Lixte Biotechnology Holdings Inc, H1 2017 Traumatic Brain Injury - Pipeline by MandalMed Inc, H1 2017 Traumatic Brain Injury - Pipeline by Mapreg SAS, H1 2017 Traumatic Brain Injury - Pipeline by Neuralstem Inc, H1 2017 Traumatic Brain Injury - Pipeline by Neuren Pharmaceuticals Ltd, H1 2017 Traumatic Brain Injury - Pipeline by Neurofx Inc, H1 2017 Traumatic Brain Injury - Pipeline by NeuroNascent Inc, H1 2017 Traumatic Brain Injury - Pipeline by NeuroVive Pharmaceutical AB, H1 2017 Traumatic Brain Injury - Pipeline by New World Laboratories Inc, H1 2017 Traumatic Brain Injury - Pipeline by NuvOx Pharma LLC, H1 2017 Traumatic Brain Injury - Pipeline by Omeros Corp, H1 2017 Traumatic Brain Injury - Pipeline by Oxeia Biopharmaceuticals Inc, H1 2017 Traumatic Brain Injury - Pipeline by PharmatrophiX Inc, H1 2017 Traumatic Brain Injury - Pipeline by Phylogica Ltd, H1 2017 Traumatic Brain Injury - Pipeline by Prevacus Inc, H1 2017 Traumatic Brain Injury - Pipeline by QR Pharma Inc, H1 2017 Traumatic Brain Injury - Pipeline by RegeneRx Biopharmaceuticals Inc, H1 2017 Traumatic Brain Injury - Pipeline by Remedy Pharmaceuticals Inc, H1 2017 Traumatic Brain Injury - Pipeline by Sage Therapeutics Inc, H1 2017 Traumatic Brain Injury - Pipeline by SanBio Inc, H1 2017 Traumatic Brain Injury - Pipeline by STATegics Inc, H1 2017 Traumatic Brain Injury - Pipeline by Stemedica Cell Technologies Inc, H1 2017 Traumatic Brain Injury - Pipeline by SynZyme Technologies LLC, H1 2017 Traumatic Brain Injury - Pipeline by Tetra Discovery Partners LLC, H1 2017 Traumatic Brain Injury - Pipeline by Thera Neuropharma Inc, H1 2017 Traumatic Brain Injury - Pipeline by vasopharm GmbH, H1 2017 Traumatic Brain Injury - Pipeline by VG Life Sciences Inc, H1 2017 Traumatic Brain Injury - Dormant Projects, H1 2017 Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..1), H1 2017 Traumatic Brain Injury - Dormant Projects, H1 2017 (Contd..2), H1 2017 Traumatic Brain Injury - Discontinued Products, H1 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
